China fines pharma firm US$1.3b in vaccine scandal
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BEIJING] Chinese authorities have slapped a fine and asset seizure totalling a whopping US$1.3 billion on a pharmaceutical company over a vaccine scandal that fuelled public fears of domestically-made medicine, drug regulators said Tuesday.
The massive fine is the latest move by authorities to punish Changchun Changsheng Biotechnology company, based in northeast Jilin province, over the faulty rabies vaccine.
The firm's chairwoman and 14 other people were arrested in connection with the scandal in July, while a slew of national, provincial and local officials have been sacked.
The manufacturer of rabies vaccines was ordered to cease production after it was found to have fabricated records.
Authorities say the suspect rabies vaccines did not enter the market. But the case provoked outrage from consumers fed up with recurring product-safety scandals, particularly in the drug sector.
The company was handed a fine and asset seizure totalling US$1.3 billion, the China National Drug Administration (CNDA) Jilin Food and Drug Administration said Tuesday.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
The amount includes the forfeiture of 1.89 billion yuan(S$375.9 million) in revenue from the sale of the vaccine.
AFP
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Beijing’s calculated silence on the Iran war
Middle East-linked energy supply shocks put Asean Power Grid back in focus